Skip to main content


UEG Week Virtual 2020

medwireNews covered UEG Week Virtual, watch our expert videos on some of the major trials. 

Expert interviews from UEG Week Virtual 2020

Brian Feagan

19-10-2020 | Gastroenterology | Video

UEGW 2020 | Filgotinib shows efficacy as induction therapy for moderate to severe UC

Brian Feagan shares the SELECTION study findings showing a role for filgotinib in the treatment of biologic-naive and experienced patients with moderately to severely active ulcerative colitis (10:21).

Silvio Danese

14-10-2020 | Gastroenterology | Video

UEGW 2020 | Treat-to-target aids ustekinumab dosing in patients with Crohn’s disease

Silvio Danese discusses the STARDUST trial looking at the benefits of a treat-to-target strategy for optimising ustekinumab treatment in Crohn’s disease based on endoscopic and clinical outcomes (3:28).

Silvio Danese

14-10-2020 | Gastroenterology | Video

UEGW 2020 | Ozanimod maintains remission in patients with ulcerative colitis

Silvio Danese outlines the 52-week TRUE NORTH study findings showing the benefits of ozanimod in patients with moderate-to-severe ulcerative colitis (4:11).

Ryan Ungaro

14-10-2020 | Gastroenterology | Video

UEGW 2020 | Corticosteroids but not TNF-inhibitors increase severe COVID-19 outcomes risk

Ryan Ungaro reports results from the updated SECURE-IBD registry looking at the impact patient characteristics and immunosuppressants have on COVID-19 outcomes in patients with IBD (5:45).

Peter Bossuyt

12-10-2020 | Gastroenterology | Video

UEGW 2020 | Ultraproactive therapeutic drug monitoring does not outperform reactive in IBD

Peter Bossuyt discusses his pragmatic trial looking at the potential of ultraproactive therapeutic drug monitoring to improve infliximab dosing in patients with inflammatory bowel disease (5:38).

14-08-2018 | Oncology | News | Article

Preoperative antivirals lower recurrence risk in HBV-related liver cancer

Patients who receive antiviral therapy for more than 90 days prior to hepatectomy for hepatitis B virus-related hepatocellular carcinoma have a reduced risk for microvascular invasion and early tumor recurrence, Chinese research shows.

05-04-2018 | Gastrointestinal cancer | News | Article

Treating H. pylori reduces metachronous gastric cancer risk

Antibiotic therapy for Helicobacter pylori in patients with early gastric cancer is associated with a 50% lower risk for subsequent disease, trial findings indicate.

World map

03-08-2018 | HBV | News | Article

Global HBV prevalence estimated at 3.9%

More than 290 million people, or 3.9% of the global population, are infected with hepatitis B virus, and while efforts to combat infection are improving, greater access to diagnosis and treatment is needed to meet global targets, report The Polaris Observatory Collaborators.

22-09-2017 | HBV | News | Article

High metabolic risk burden increases HCC risk in HBV patients

A high burden of metabolic risk factors significantly increases the risk for hepatocellular carcinoma among men with hepatitis B virus infection, particularly those who smoke, researchers from Taiwan report.

Follow medwireNews

Click here